Myc is a transcription factor that controls growth, survival and microenvironment of tumour cells and is deregulated in many tumour types, but has until now resisted efforts to develop effective inhibitors. Hence, Myc has become a most wanted target for cancer therapy. Peptomycis a SME that develops innovative drug products and research tools to selectively target Myc. Our first clinical candidate, OMO-103, derives from Omomyc, the best Myc inhibitor known to date that benefits from 20 years of preclinical validation. Thanks to this H2020 SME Instrument project MYCure, OMO-103 will become a marketed first-in-class Myc inhibitor for lung cancer treatment, extending the life and health status of thousands of patients.


The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 872212.